WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018004240) USE OF NUPR1 IN DIAGNOSIS AND TREATMENT OF BRAIN TUMOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/004240    International Application No.:    PCT/KR2017/006783
Publication Date: 04.01.2018 International Filing Date: 27.06.2017
IPC:
G01N 33/574 (2006.01), A61K 48/00 (2006.01), A61K 39/395 (2006.01), A61K 39/00 (2006.01)
Applicants: OPTIPHARM CO., LTD [KR/KR]; 63, Osongsaengmyeong 6-ro, Osong-eup Cheongwon-gun Chungcheongbuk-do 28158 (KR).
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION [KR/KR]; 1, Gwanak-ro Gwanak-gu Seoul 08826 (KR)
Inventors: PAEK, Sun Ha; (KR).
KIM, Yo Na; (KR).
HAN, Beom Ku; (KR).
OH, Mi Kyoung; (KR).
SONG, Min Kyu; (KR).
KIM, Hyun Il; (KR)
Agent: KIM, Soon Woong; (KR)
Priority Data:
10-2016-0080044 27.06.2016 KR
10-2017-0081199 27.06.2017 KR
Title (EN) USE OF NUPR1 IN DIAGNOSIS AND TREATMENT OF BRAIN TUMOR
(FR) UTILISATION DE NUPR1 DANS LE DIAGNOSTIC ET LE TRAITEMENT DE LA TUMEUR AU CERVEAU
(KO) 뇌종양의 진단 및 치료에서의 NUPR1의 용도
Abstract: front page image
(EN)The present invention relates to use of nuclear protein 1 (NUPR1) in diagnosing and treating brain tumors and, more particularly, to a biomarker composition comprising NUPR1 for diagnosing brain tumors or for predicting prognosis and a composition comprising an NUPR1 inhibitor for preventing or treating brain tumors. The level of NUPR1, particularly NUPR1 isoform A, according to the present invention is significantly increased in patients with brain tumors and further remarkably in patients with malignant brain tumors of poor prognosis, compared to healthy normal persons, so that NUPR1 can be used as a biomarker for diagnosis of brain tumors or for prediction of prognosis. In addition, NUPR1, particularly NUPR1 isoform A according to the present invention can be used as a target for brain tumor treatment and also, in future, in screening a therapeutic agent for brain tumors as the inhibition thereof can suppress the growth, metastasis and invasion of brain tumors.
(FR)La présente invention concerne l’utilisation d’une protéine nucléaire (1) (NUPR1) dans le diagnostic et le traitement des tumeurs au cerveau et, plus particulièrement, une composition de biomarqueur comprenant NUPR1 pour le diagnostic des tumeurs au cerveau ou pour prédire le prognostic et une composition comprenant un inhibiteur NUPR1 pour prévenir ou traiter les tumeurs au cerveau. Le niveau de NUPR1, particulièrement l’isoforme (A) de NUPR1, selon la présente invention, est significativement accru chez les patients présentant des tumeurs au cerveau et remarquablement en outre chez les patients présentant des tumeurs malignes au cerveau d’un prognostic médiocre, comparé aux personnes normales saines, de telle sorte que NUPR1 peut être utilisé comme biomarqueur pour le diagnostic des tumeurs au cerveau ou pour la prédiction d’un prognostic. De plus, NUPR1, particulièrement l’isoforme (A) de NUPR1, selon la présente invention, peut être utilisé comme cible de traitement de la tumeur au cerveau et également, dans le futur, dans le criblage d’un agent thérapeutique pour les tumeurs au cerveau dans la mesure où son inhibition peut supprimer la croissance, la métastase et l’invasion de tumeurs au cerveau.
(KO)본 발명은 뇌종양의 진단 및 치료에서의 NUPR1의 용도에 관한 것으로, 보다 구체적으로 본 발명은 NUPR1(Nuclear protein 1)을 포함하는 뇌종양 진단 또는 예후 예측용 바이오 마커 조성물 및 NUPR1 억제제를 포함하는 뇌종양 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 NUPR1, 특히 NUPR1 동형 A는 건강한 정상인에 비해 뇌종양 환자에서 유의하게 증가하며, 특히 예후가 나쁜 악성 뇌종양 환자에서 더욱 현저하게 증가하는바, 이를 뇌종양 진단 또는 예후 예측용 바이오 마커로 활용할 수 있다. 또한, 본 발명에 따른 NUPR1, 특히 NUPR1 동형 A의 억제를 통해 뇌종양의 성장, 전이 및 침입을 억제할 수 있는바, 이를 뇌종양 치료를 위한 타겟으로 활용할 수 있고, 향후 뇌종양 치료제의 스크리닝에도 이용할 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)